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ORIGINAL ARTICLE
Does Colonoscopy Cause Increased Ulcerative Colitis
Symptoms?
Stacy Menees, MD,* Peter Higgins, MD,† Sheryl Korsnes, MA,† and Grace Elta, MD†
Background: Ulcerative colitis (UC) patients often report symp-
tom flares after colonoscopy. However, this has not been docu-
mented in the literature.
Objectives: 1. Determine whether colonoscopy is associated with
increased UC symptoms. 2. Determine whether there is a need for
escalation of UC medications after colonoscopy. 3. Identify baseline
variables associated with increased symptoms after colonoscopy.
Methods: Firty-five outpatients with a history of UC, intact colon,
and quiescent disease were enrolled in a prospective case-crossover
study. Subjects were evaluated with the Simple Clinical Colitis
Activity Index (SCCAI) before colonoscopy, 1 week and 4 weeks
after colonoscopy. A mixed model analysis was used to accommo-
date nonindependence of repeated measurements on the same pa-
tients.
Results: Fifty-one (91%) subjects completed the study. Six sub-
jects had clinical relapse defined by a score of 5 or greater on the
SCCAI during the week after colonoscopy. Five subjects increased
their 5-aminosalicylic acid (5-ASA) medications immediately post-
colonoscopy, two of whom had a SCCAI 5 or greater. Multivariate
modeling demonstrated a clear association between the week imme-
diately after colonoscopy preparation and increased disease activity,
with the time period being predictive of increased SCCAI (week 1
vs. week 4, P  0.0127). The baseline SCCAI (P value  0.0001)
and prednisone use (P  0.0120) were predictive of increased
SCCAI postcolonoscopy. Thiopurines (P  0.001) were protective
against increased symptoms.
Conclusions: In our study, 1 in 8 subjects had UC relapse by
SCCAI immediately postcolonoscopy, and 1 in 10 subjects required
an increase in their 5-ASA medications. Clinicians should be cog-
nizant of this effect of colonoscopy in patients with UC.
(Inflamm Bowel Dis 2007;13:12–18)
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Colonoscopy is a commonly used tool in the diagnosisand management of ulcerative colitis (UC). The early
literature suggests an association between colonoscopy prep-
aration and toxic megacolon in severe UC.1–4 Previous re-
ports have also demonstrated left-sided colonic mucosal ul-
cerations secondary to sodium phosphate and polyethylene
glycol.5–12 Additional studies have found an association be-
tween residual glutaraldehyde on endoscopes and colitis
symptoms in patients without UC.13–23
However, no trials have directly assessed the impact of
colonoscopy on UC symptoms. Anecdotally, we have noted
an increase in symptoms in UC patients after colonoscopy.
The etiology of this phenomenon is unknown. Animal models
have shown that agents that induce ulceration in the colon
(i.e., piroxicam) can promote colitis, and hypertonic colonos-
copy preparations may produce the same effect in patients.24
The aims of our study were to assess the following: 1) the
relationship of colonoscopy to disease activity in UC; 2) the
necessity of steroids or escalation of UC medications within
4 weeks after colonoscopy; and 3) the identification of de-
mographic factors, disease characteristics, or medications as-
sociated with increased symptoms after colonoscopy.
MATERIALS AND METHODS
Selection of Patients
This study was conducted at a large academic hospital
endoscopy unit between October 2004 and October 2005.
With investigational review board approval, a prospective
cohort of patients was approached in the waiting room before
their colonoscopy appointment. Participants aged 18 and
older with established UC by biopsy were eligible for partic-
ipation. The indication for colonoscopy in each patient was
colon cancer surveillance. Patients without an intact colon
and patients with active symptoms identified by an affirma-
tive answer to the question “Are you having this colonoscopy
for an increase in your symptoms?” were excluded from our
study. For our initial sample size calculation, we estimated
that the average Simple Clinical Colitis Activity Index (SC-
CAI) increase in subjects after colonoscopy preparation
would be 2 points, with a standard deviation of 2. With a
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power of 80% and a two-sided alpha of 0.05, this produced a
sample size of 29 subjects. We added two subjects to allow
for dropouts, producing a sample size of 31. Because these
were only crude estimates of the event rate and effect size, an
interval data analysis was planned at a cost of 0.01 in P value
at 31 subjects. This preliminary analysis revealed a smaller
effect size than estimated, and the sample size was adjusted to
51 subjects, with a threshold of P less than 0.04 for statistical
significance in the final analysis.
Study Design
A crossover study design was used to determine subject
outcomes after colonoscopy.25 This is a well-established
study design that uses statistical techniques that are an ex-
tension of the paired t test. This design is appropriate when an
intermittent exposure (colonoscopy) may increase the risk of
an outcome (UC flare) over a short period of time, and this
effect “washes out” quickly. This design compares each sub-
ject’s outcome during a period of exposure with the putative
risk factor to the subject’s outcome during a period of non-
exposure. A mixed-model analysis allows matching of each
subject to themselves across time periods, much like a paired
t test. Because each subject serves as their own control,
variability is reduced, producing increased statistical power
for this pilot study. This is commonly performed retrospec-
tively; however, this approach can be applied to prospective
studies with short exposures to a putative risk factor, and the
mixed model analysis allows the assessment of the affect of
other covariates on disease activity.26,27
Our subjects had baseline disease activity measure-
ments from the week before colonoscopy, which allowed us
to control for the baseline disease activity when evaluating
the effect of the colonoscopy preparation. One week after
colonoscopy, we measured the effects of exposure to
colonoscopy preparation. By the fourth week, we assumed
that the preparation effect would wash out. We then measured
disease activity during the fourth week when there was again
no exposure to the colonoscopy preparation.
Data on potentially relevant covariates was collected in
a precolonoscopy survey. This survey of 21 questions col-
lected demographic data including the subjects’ age, sex, and
racial group. Information relevant to the subjects’ UC history
such as duration of diagnosis, current UC medications, aver-
age number of flares per year, corticosteroid use, or hospi-
talizations in the past 5 years was also collected. Risk factors
for UC relapse were also obtained including smoking history/
recent smoking cessation, medication compliance history,
nonsteroidal anti-inflammatory drug use, and antibiotic use.
To measure disease activity, subjects were asked to
complete the SCCAI at the time of colonoscopy (week 0) and
1 week and 4 weeks after colonoscopy. This instrument was
developed by Walmsley et al28 and further validated by
Jowett et al29 in 2003, when a threshold of 5 or more points
was defined as a relapse. The SCCAI is a survey of six
questions with a point system that measures UC symptoms.
The SCCAI specifically assesses the urgency and number of
bowel movements, the presence and the amount of blood in
the stool, the occurrence and number of nocturnal bowel
movements, the presence of extracolonic manifestations, and
the patient’s general well-being. In 2005, Higgins et al30
found that endoscopy contributed little additional information
in the assessment of UC disease activity and that non-inva-
sive indices such as the SCCAI could accurately assess dis-
ease activity.
The initial SCCAI assessment was performed in person
before colonoscopy, and phone surveys were performed 1
week and 4 weeks after colonoscopy consisting of the SCCAI
and additional questions that assessed the need for an increase
in UC medications, corticosteroids, or hospitalizations. Sub-
jects who were unable to be contacted for their preassigned
phone interviews (at week 1 or 4) were excluded from further
study involvement.
The primary endpoint of our study was to evaluate the
effect of exposure to colonoscopy on the change in the
continuous outcome of the SCCAI. As a secondary outcome,
we planned to evaluate the dichotomous outcome of UC
relapse, as defined by (2a) the need for either 5-aminosali-
cylic acids (5-ASA), prednisone, or hospitalization for in-
creased symptoms, or (2b) a SCCAI score of 5 or greater
indicating UC disease relapse. We report the incidence of
these dichotomous outcomes, but flare events were too infre-
quent (10 by both definitions) to allow an analysis of the
effects of covariates on the likelihood of flare. Because the
exposure to the colonoscopy preparation and the colonoscopy
itself were nearly coincident, this design does not allow us to
determine whether the preparation or the colonoscopy itself is
associated with increased symptoms of colitis.
Data Analysis
The primary endpoint was disease activity as measured
by the SCCAI, which was evaluated initially with paired t
tests to compare the SCCAI values at each evaluation time
point in an initial analysis. The SCCAI was then treated as the
dependent variable in a mixed-model analysis. The baseline
SCCAI at week 0 was included as an independent covariate
in all models. The exposure to colonoscopy was treated as an
independent variable and was coded as 1 for week 1 (expo-
sure to preparation) and 0 for week 4 (no exposure). Addi-
tional potential covariates were tested one by one in a biva-
riate analysis (with the baseline SCCAI) to determine the
estimated coefficient and significance of each covariate. A
multivariate mixed model was then constructed using the
baseline SCCAI and all of the potential covariates that had a
P value of less than 0.3 in the bivariate analysis. The least
significant variables were then removed from the model one
by one until the model was constructed only of factors with
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P values of 0.05 or less. Potential factors were then added
back one by one and tested for significance. The final model
was a multivariate mixed model using type 3 tests of fixed
effects and an autoregressive variance model.
The secondary endpoint of UC symptom flare is re-
ported for both definitions of flare. Because fewer than 10
flare events occurred for each definition of flare, no analysis
of the effect of covariates on the likelihood of flare was
performed. All analyses were conducted using two-sided
tests. The threshold for statistical significance for the final
analysis was set at 0.04 because of the interim analysis
performed after 31 subjects were enrolled. Analyses were
performed with SAS version 9.1 (Cary, NC).
RESULTS
A total of 55 subjects were enrolled before colonos-
copy. Fifty-one subjects completed the study (91% comple-
tion rate) (Fig. 1). The median age of the participants was 49
(range, 22–78) years, 55% of the subjects were men, and 96%
were white. Participants had a history of UC for a average of
12 (range, 1–54) years. For colonoscopy preparation, 79% of
subjects used fleets phosphosoda. The rest of the subjects
(21%) used polyethylene glycol solution as their colonoscopy
preparation. Table 1 lists additional data detailing the demo-
graphics, disease history, and medications of our subject
sample.
Data was also collected regarding possible confounders
such as medication noncompliance, antibiotic use, nonsteroi-
dal anti-inflammatory drug (NSAID) use, and smoking ces-
sation, which may contribute to an increase in UC symptoms.
Fifty-three percent of subjects reported never forgetting to
take their UC medication, whereas 14% forgot their medica-
tion once per month, 17% forgot once per week, and 4%
forgot once per day. Interestingly, only 18% of subjects
reported forgetting a dose of their medication within 1 week
of their colonoscopy. All subjects denied recent smoking
cessation, whereas 18% of subjects reported NSAID use
within the week before colonoscopy, and 14% had reported
recent antibiotic use. Only 10% of subjects believed at the















5-aminosalicylic acid 36 71
Thiopurines 15 29
Prednisone 10 20
No UC medication 7 16
Median Range
Baseline UC disease activity
Length of disease (yr) 12 1–54
Hospitalizations in last 5 yr 0 0–5
Flares per year 2.0 2–12
Flares requiring steroids in last 5 yr 0 0–12
Baseline SCCAI 1.0 0–9
SCCAI, Simple Clinical Colitis Activity Index.
FIGURE 1. Plot of individual and loess smoothed Simple Clini-
cal Colitis Activity Index (SCCAI) at baseline, week 1 and week 4.
Subject’s SCCAI score at week 0, 1, and 4 (gray lines). One gray
line may represent multiple subjects. Loess smoothed average
SCCAI for all patients (black line). Statistically significant differ-
ences between SCCAI measured at week 0 versus week 1, P
 0.0013, and week 1 and week 4, P  0.0001, were found
with paired t tests. No statistically significant difference be-
tween week 4 SCCAI and week 0 baseline SCCAI, P  0.1599.
Average SCCAI measured at baseline, week 1, and week 4.
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start of the study that colonoscopy preparation caused a flare
in their UC symptoms, and 6% of subjects were unsure if
colonoscopy preparation had any effect on their UC symp-
toms.
The baseline median SCCAI score for the week before
colonoscopy was 1.0 (range, 0–9.0). During the week post-
colonoscopy, the median SCCAI was 2.0 (range, 0–9), and
during the fourth week postcolonoscopy, the median SCCAI
was 1.0 (range, 0–9) (Fig. 1). Using multivariate mixed
modeling, we identified statistically significant predictors of
increased SCCAI postcolonoscopy (Tables 2 and 3). Predic-
tors associated with worsening SCCAI postcolonoscopy in-
cluded the exposure to colonoscopy, week 1 versus week 4 (P
 0.0127), higher baseline SCCAI (P  0.0001), and the
use of prednisone at the time of colonoscopy (P  0.0120).
Protective factors against an increased SCCAI postcolonos-
copy included maintenance thiopurines (P  0.0045), and
there was a trend toward a protective effect of female sex (P
 0.1188). Using the coefficients obtained from the multi-
variate mixed model, one can predict the average SCCAI
score during the week after colonoscopy, as illustrated in
Table 4.
The sample size of our study was calculated for the
continuous primary endpoint of SCCAI score; consequently,
our study was underpowered for the secondary dichotomous
endpoints of UC flare (need for UC medications or SCCAI
 5). However, these dichotomous endpoints generally have
greater clinical relevance than changes in continuous scales;
therefore, we evaluated the significant covariates from the
multivariate model for SCCAI to determine whether they had
effects on clinically relevant outcomes.
For the secondary endpoint of UC flare as defined by
the need for additional UC medications, a total of eight (16%)
subjects had a flare of their UC symptoms. Five subjects
required an increase in their 5-ASA medications the week
immediately postcolonoscopy, and two of these subjects also
fulfilled our primary endpoint with a SCCAI score of 5 or
greater. The other three subjects increased their 5-ASA med-
ications for worsening symptoms for a 1 to 3 point increase
in their SCCAI. Between week 1 and week 4, three additional
subjects increased their UC medications because of perceived
worsening of symptoms. Interestingly, two of these subjects
had an unchanged SCCAI score, whereas the last subject’s
SCCAI improved by 1 point. No subjects required the use of
prednisone or were hospitalized for an increase in symptoms
postcolonoscopy.
We also evaluated the secondary dichotomous endpoint
of UC relapse as defined by Jowett et al29 as an SCCAI of 5
or greater. With use of this definition, six subjects had a
clinical relapse in the week after colonoscopy. Four weeks
postcolonoscopy, only one of the six subjects continued to
have disease relapse, with a SCCAI of 7. This suggests that
this effect does largely wash out between week 1 and week 4.
TABLE 2. Bivariate Analysis of Simple Clinical Colitis Activity
Index (SCCAI) Outcome with Baseline SCCAI as Second
Covariate
Variable Estimate P Value
Colonoscopy variables
Week before colonoscopy 0.6471 0.001
Golytely preparation 0.0577 0.9192








Years of UC (decade) 0.3932 0.0688
Hospitalizations in last 5 yr 0.1744 0.4382
Flares/yr 0.2073 0.0072
No. of steroids/5 yrs 0.1895 0.0311
Baseline SCCAI 0.5369 0.0001
Medication regimen
5-aminosalicylic acid use 0.3222 0.5422





Never smoked 0.0582 0.9044
Thiopurine use 0.8611 0.8708




Positive estimates are associated with increased SCCAI scores, whereas
negative estimates are associated with decreased SCCAI scores.
UC, ulcerative colitis; NSAIDS, nonsteroidal anti-inflammatory drugs.
TABLE 3. Multivariate Analysis of Simple Clinical Colitis
Activity Index (SCCAI) Outcome
Variable Estimate P Value
Intercept 1.0747 0.0029
Week 1 (post colon prep) vs. week 4 0.6471 0.0127
Baseline SCCAI 0.4636 0.0001
Thiopurine use 1.3542 0.0045
Prednisone use 1.4359 0.0120
Female sex 0.5677 0.1188
Positive estimates are associated with increased SCCAI scores, whereas
negative estimates are associated with decreased SCCAI scores.
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DISCUSSION
Colonoscopy is a widely used procedure for diagnosis,
disease assessment, and cancer surveillance in UC. Our re-
sults suggest that recent colonoscopy can cause a mild relapse
in UC symptoms; this is not affected by concomitant NSAID,
antibiotic use, smoking cessation, or the type of colonoscopy
preparation. This finding is most prominent in the week
immediately after colonoscopy and largely resolves by the
fourth week after colonoscopy. The etiology of this associa-
tion is unknown. Previous studies have described colonic
mucosal abnormalities associated with sodium phosphate
preparation and polyethylene glycol.5–12 These mucosal ab-
normalities are primarily visualized in the left colon in 2.6%
to 24.5% of colonoscopies. In all of these studies, the subjects
were clinically asymptomatic. Driman and Preiksaitis8 dem-
onstrated an increase in crypt cell apoptosis and crypt epi-
thelial proliferation in the mucosa affected by colonoscopy
preparation. These changes are thought to be metabolically
induced rather than secondary to direct topical injury. Animal
model studies have shown that agents that induce ulceration
in the colon can also promote colitis24 and that standard
preparations may cause oxidative stress that leads to colonic
mucosal damage.31
Beyond the described mucosal changes, colonoscopy
preparation has been identified as a trigger in precipitating
toxic megacolon. General clinical consensus since the early
1980s has been to avoid colonoscopy preparation in the
severely ill UC patient and if necessary to proceed only with
an unprepped flexible sigmoidoscopy for evaluation.1–4 The
etiology for this association between preparation and toxic
megacolon is unknown, although electrolyte disturbances and
the release of inflammatory mediators have been suggested as
predisposing factors leading to inhibitory effects on colonic
muscular tone.32–35 An alternative explanation of this phe-
nomenon is that the induction of increased disease activity is
caused by the colonoscopy itself. This could be caused by
direct trauma to the mucosa by biopsies or looping, increas-
ing mucosal permeability to colonic bacteria. Alternatively,
UC patients with increased mucosal permeability may be
especially sensitive to small amounts of residual glutaralde-
hyde on colonoscopes.
In our study, 10% of our subjects required an increase
in 5-ASA medications within a week of colonoscopy; how-
ever, none required corticosteroids or hospitalization. Sur-
prisingly, the SCCAI did not always predict the perceived
need for increased UC medication. Four subjects with SCCAI
5 or greater did not require an increase in medications,
whereas three subjects with a score less than 5 increased their
medications. The reason for this discordance is unknown;
however, presumably there are some unmeasured variables
that contribute to the subject’s perception of a flare. Anec-
dotally, we have also observed that some subjects require
hospitalization for postcolonoscopy UC flares. However, our
study size was underpowered to assess this uncommon event.
The subject’s baseline SCCAI and the use of chronic
prednisone were both directly related to their likelihood of
experiencing a flare. A higher baseline SCCAI and chronic
prednisone dependence likely both identify subjects with
more tenuous control of their UC symptoms. This is sup-
ported by Faubion’s36 study of the natural history of cortico-
steroid initiation for IBD in Olmsted County. Only 49% of
UC patients maintained remission without surgery or pro-
longed corticosteroid therapy over the following year, indi-
cating that the need for corticosteroid therapy was a marker of
relatively poor prognosis.
In our cohort, the use of thiopurines was protective
against UC symptom recurrence. Thiopurines are immuno-
modulators used as second-line treatment when 5-ASA med-
ications prove ineffective. Thiopurines used for maintenance
therapy in UC have been shown by some studies to be
effective steroid-sparing agents.37–41 Hawthorne et al39 con-
ducted a 1 year randomized controlled trial of azathioprine
withdrawal in UC patients and found a relapse rate of 59% for
patients on placebo compared with 36% for patients who
continued on azathioprine. Our study is significant in that it
shows both a strong association between colonoscopy expo-
sure and increased UC symptoms and also shows that thio-
TABLE 4. Estimates of Effects of Each Variable in Multivariate Model Used to Predict Average SCCAI at 1 Week after Colonoscopy











at Week 1 after
Colonoscopy
Male on prednisone,
baseline SCCAI  4
1.0747 0.6471 4*.4636  1.85 1.4359 0 0 5.01
Female on thiopurine,
baseline SCCAI  4
1.0747 0.6471 4*.4636  1.85 0 1.3542 0.5677 1.65
As shown, a male patient on chronic steroids with a baseline SCCAI of 4 would be expected to have a mild relapse, defined by Jowett et al as SCCAI  5.
In contrast, a female patient with the same baseline SCCAI, but on thiopurines, would on average have minimal symptoms 1 week after colonoscopy.
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purine use is associated with decreased UC symptoms after
colonoscopy preparation.
Interestingly, in our study population, there was also a
trend toward significance relative to the participant’s sex,
with women being less likely to experience a flare from
colonoscopy preparation. The lack of statistical significance
may be secondary to inadequate power. However, no data in
the IBD literature has ever shown sex as a predictor of the
patient’s subsequent course of this chronic disease.
There are several potential limitations to this study.
First, our study involved ambulatory patients referred to a
single tertiary care center, and thus, our patient population
may not be representative of the community setting. Al-
though subjects were not randomized, they served as their
own controls, and the crossover design reduces the variability
from unmeasured confounders that are constant across time
such as age or sex. However, this design does not control for
variables that change over time, including the subjects’ self-
adjustment of their medication dosing. We did not expect to
see frequent self-adjustment of 5-ASA medication dosing by
subjects without consulting their gastroenterologists, but this
clearly occurs and may confound the results of this and other
clinical studies. Third, 4 of our 55 subjects were unable to be
contacted for follow-up surveys, and their data could affect
the significance of our results. Fourth, our analysis assumes
that the risk of increased disease activity during the period of
colonoscopy is caused by the preparation. This is not neces-
sarily true. Any factor that is associated with the colonos-
copy, including the procedure itself, or any residue of the
cleaning solution, glutaraldehyde, left on the colonoscopes
could potentially cause the effects we found.21,42,43 It is
possible that UC patients are particularly sensitive to small
amounts of glutaraldehyde because of their increased muco-
sal permeability. Also, we may have introduced bias in our
study by asking the subjects to assess their bowel symptoms
after colonoscopy, possibly causing these patients to exag-
gerate their symptoms.
In designing this pilot study, we were unsure of the
impact that colonoscopy would have on the disease course of
UC. Therefore, we thought it judicious to use a continuous
variable (change in SCCAI) as our primary endpoint. How-
ever, by using the change in SCCAI as our primary endpoint,
it made our study size significantly smaller and limited our
power to look at dichotomous endpoints such as the need for
increased UC medication postcolonoscopy. We can now use
these data in future studies to power for more clinically useful
endpoints. Finally, our study relied on self-reporting for the
week before surveys, and the imprecision of recalled symp-
toms could affect or possibly bias our results.
Previously, the association between UC relapse and
colonoscopy in quiescent patients has been anecdotal. In this
pilot study, we show a significant association between
colonoscopy and an increase in UC symptoms, most promi-
nent in the week immediately after colonoscopy. Sixteen
percent of our subjects had UC flare as defined by SCCAI 5
or greater, whereas 10% required an increase in their 5-ASA
medications immediately postcolonoscopy. The relapse is
mild, at most requiring an increase in 5-ASA medications in
this sample, and typically resolving within a few weeks. Both
the baseline SCCAI and the use of prednisone were predictive
of disease flare, whereas chronic thiopurine use was protec-
tive. Clinicians should be aware of this effect of preparation
for colonoscopy or the colonoscopy itself in patients with
UC.
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